• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卡塔尔 10 个社区中严重急性呼吸综合征冠状病毒 2 感染的群体免疫。

Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar.

出版信息

Emerg Infect Dis. 2021 May;27(5):1343-1352. doi: 10.3201/eid2705.204365.

DOI:10.3201/eid2705.204365
PMID:33900174
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8084480/
Abstract

We investigated what proportion of the population acquired severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and whether the herd immunity threshold has been reached in 10 communities in Qatar. The study included 4,970 participants during June 21-September 9, 2020. Antibodies against SARS-CoV-2 were detected by using an electrochemiluminescence immunoassay. Seropositivity ranged from 54.9% (95% CI 50.2%-59.4%) to 83.8% (95% CI 79.1%-87.7%) across communities and showed a pooled mean of 66.1% (95% CI 61.5%-70.6%). A range of other epidemiologic measures indicated that active infection is rare, with limited if any sustainable infection transmission for clusters to occur. Only 5 infections were ever severe and 1 was critical in these young communities; infection severity rate of 0.2% (95% CI 0.1%-0.4%). Specific communities in Qatar have or nearly reached herd immunity for SARS-CoV-2 infection: 65%-70% of the population has been infected.

摘要

我们调查了卡塔尔 10 个社区中有多少人口感染了严重急性呼吸综合征冠状病毒 2(SARS-CoV-2),以及群体免疫阈值是否已经达到。该研究包括 2020 年 6 月 21 日至 9 月 9 日期间的 4970 名参与者。使用电化学发光免疫分析法检测 SARS-CoV-2 抗体。血清阳性率在社区之间从 54.9%(95%CI 50.2%-59.4%)到 83.8%(95%CI 79.1%-87.7%)不等,平均为 66.1%(95%CI 61.5%-70.6%)。一系列其他流行病学指标表明,活跃感染很少见,集群发生任何可持续的感染传播的可能性都很有限。在这些年轻的社区中,仅有 5 例感染是严重的,其中 1 例是危急的;感染严重率为 0.2%(95%CI 0.1%-0.4%)。卡塔尔的一些特定社区已经或几乎达到了 SARS-CoV-2 感染的群体免疫水平:65%-70%的人口已经感染。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a8a/8084480/a1c4e23fe3b3/20-4365-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a8a/8084480/6a34fa5eefff/20-4365-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a8a/8084480/a1c4e23fe3b3/20-4365-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a8a/8084480/6a34fa5eefff/20-4365-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a8a/8084480/a1c4e23fe3b3/20-4365-F2.jpg

相似文献

1
Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar.卡塔尔 10 个社区中严重急性呼吸综合征冠状病毒 2 感染的群体免疫。
Emerg Infect Dis. 2021 May;27(5):1343-1352. doi: 10.3201/eid2705.204365.
2
SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar.在卡塔尔大部分人口中,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染已达到群体免疫。
Open Forum Infect Dis. 2021 May 2;8(8):ofab221. doi: 10.1093/ofid/ofab221. eCollection 2021 Aug.
3
Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February-18 April 2020.2020 年 2 月 28 日至 4 月 18 日,卡塔尔对 5685 例 SARS-CoV-2 感染病例的首次流行病学调查。
BMJ Open. 2020 Oct 7;10(10):e040428. doi: 10.1136/bmjopen-2020-040428.
4
Severe acute respiratory syndrome-coronavirus-2 seroprevalence study in Pimpri-Chinchwad, Maharashtra, India coinciding with falling trend - Do the results suggest imminent herd immunity?印度马哈拉施特拉邦平浦尔-钦奇瓦德地区严重急性呼吸综合征冠状病毒 2 血清流行率研究恰逢下降趋势——这些结果是否表明即将出现群体免疫?
Indian J Public Health. 2021 Jul-Sep;65(3):256-260. doi: 10.4103/ijph.IJPH_122_21.
5
Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi-challenges in acquiring herd immunity for COVID 19.卡拉奇居民的抗 SARS-CoV-2 抗体血清阳性率——新冠病毒群体免疫面临的挑战。
J Public Health (Oxf). 2021 Apr 12;43(1):3-8. doi: 10.1093/pubmed/fdaa170.
6
Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic.描述卡塔尔严重阶段 SARS-CoV-2 疫情特征。
Sci Rep. 2021 Mar 18;11(1):6233. doi: 10.1038/s41598-021-85428-7.
7
Impact of Microbiota: A Paradigm for Evolving Herd Immunity against Viral Diseases.微生物组的影响:针对病毒病不断发展群体免疫的范例。
Viruses. 2020 Oct 10;12(10):1150. doi: 10.3390/v12101150.
8
Prevalence of hepatitis A virus among migrant workers in Qatar: A national study.在卡塔尔的农民工中甲型肝炎病毒的流行情况:一项全国性研究。
PLoS One. 2024 Jul 9;19(7):e0306753. doi: 10.1371/journal.pone.0306753. eCollection 2024.
9
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.基于 SARS-CoV-2 的免疫原性结构蛋白、宿主免疫反应和群体免疫的 COVID-19 疫苗开发的新见解。
Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.
10
Herd Immunity Against Coronavirus: A Review.群体免疫对抗冠状病毒:综述。
Recent Pat Biotechnol. 2022 Aug 3;16(3):256-265. doi: 10.2174/1872208316666220408113002.

引用本文的文献

1
Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study.ChAdOx1 nCoV-19(Vaxzevria)初级系列疫苗对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)贝塔和德尔塔变异株的有效性:一项全国性研究。
BMC Infect Dis. 2025 Aug 17;25(1):1028. doi: 10.1186/s12879-025-11410-7.
2
Immune histories and natural infection protection during the omicron era.奥密克戎时代的免疫史与自然感染防护
Commun Med (Lond). 2025 Jul 1;5(1):262. doi: 10.1038/s43856-025-00974-9.
3
Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in Qatar.

本文引用的文献

1
Differential risk for COVID-19 in the first wave of the disease among Spaniards and migrants from different areas of the world living in Spain.西班牙人和居住在西班牙的来自世界不同地区的移民在疾病的第一波中 COVID-19 的差异风险。
Rev Clin Esp (Barc). 2021 May;221(5):264-273. doi: 10.1016/j.rceng.2020.10.005. Epub 2021 Feb 27.
2
Epidemiological Differences in the Impact of COVID-19 Vaccination in the United States and China.新冠疫苗接种在美国和中国产生影响的流行病学差异
Vaccines (Basel). 2021 Mar 5;9(3):223. doi: 10.3390/vaccines9030223.
3
Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic.
评估新冠病毒疫苗有效性研究中的健康接种者效应:卡塔尔的一项全国队列研究。
Elife. 2025 Jun 9;14:e103690. doi: 10.7554/eLife.103690.
4
Protection conferred by SARS-CoV-2 infection across a spectrum of reinfection symptoms and severities.新型冠状病毒2感染对一系列再次感染症状和严重程度所提供的保护。
BMJ Open Respir Res. 2025 Mar 26;12(1):e002718. doi: 10.1136/bmjresp-2024-002718.
5
Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar.新冠疫情期间COVID-19严重程度和死亡率的转折点:卡塔尔的一项全国队列研究
BMJ Public Health. 2023 Oct 29;1(1):e000479. doi: 10.1136/bmjph-2023-000479. eCollection 2023 Nov.
6
Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron.奥密克戎毒株出现前后对新冠病毒再感染的差异保护作用。
Nature. 2025 Mar;639(8056):1024-1031. doi: 10.1038/s41586-024-08511-9. Epub 2025 Feb 5.
7
Prevalence of syphilis infection among migrant workers in Qatar: a nationwide cross-sectional survey.卡塔尔农民工梅毒感染的流行情况:一项全国性的横断面调查。
BMJ Open. 2024 Nov 27;14(11):e083810. doi: 10.1136/bmjopen-2023-083810.
8
BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar.BNT162b2 与 mRNA-1273 疫苗:卡塔尔长期预防 SARS-CoV-2 感染和重症 COVID-19 的比较分析。
Influenza Other Respir Viruses. 2024 Oct;18(10):e13357. doi: 10.1111/irv.13357.
9
SARS-CoV-2 infection prevalence, risk factors, and outcomes among non-clinical-related service providers in a national healthcare system.一个国家医疗系统中非临床相关服务提供者的新型冠状病毒2感染患病率、危险因素及转归情况
Glob Epidemiol. 2024 Jun 13;8:100149. doi: 10.1016/j.gloepi.2024.100149. eCollection 2024 Dec.
10
Prevalence of hepatitis A virus among migrant workers in Qatar: A national study.在卡塔尔的农民工中甲型肝炎病毒的流行情况:一项全国性研究。
PLoS One. 2024 Jul 9;19(7):e0306753. doi: 10.1371/journal.pone.0306753. eCollection 2024.
描述卡塔尔严重阶段 SARS-CoV-2 疫情特征。
Sci Rep. 2021 Mar 18;11(1):6233. doi: 10.1038/s41598-021-85428-7.
4
Infection fatality rate of COVID-19 inferred from seroprevalence data.基于血清流行率数据推断的 COVID-19 感染病死率。
Bull World Health Organ. 2021 Jan 1;99(1):19-33F. doi: 10.2471/BLT.20.265892. Epub 2020 Oct 14.
5
Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19.卡塔尔 2019 年冠状病毒病疫情的数学建模及其对卡塔尔 COVID-19 疫情应对措施的影响。
J Glob Health. 2021 Jan 16;11:05005. doi: 10.7189/jogh.11.05005.
6
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.对感染后长达 8 个月的 SARS-CoV-2 进行免疫记忆评估。
Science. 2021 Feb 5;371(6529). doi: 10.1126/science.abf4063. Epub 2021 Jan 6.
7
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.医护人员中抗SARS-CoV-2抗体状态及感染发生率
N Engl J Med. 2021 Feb 11;384(6):533-540. doi: 10.1056/NEJMoa2034545. Epub 2020 Dec 23.
8
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting.在高强度再暴露环境下评估严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)再感染的风险。
Clin Infect Dis. 2021 Oct 5;73(7):e1830-e1840. doi: 10.1093/cid/ciaa1846.
9
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
10
Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation.七项血清学检测的全国多中心比较揭示了新冠病毒无反应血清阴性亚群。
EClinicalMedicine. 2020 Dec;29:100651. doi: 10.1016/j.eclinm.2020.100651. Epub 2020 Nov 19.